ClinicalTrials.gg
CompletedNCT02276365Updated Oct 28, 2014

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

A Phase 1 interventional study of BI 10773 and Pioglitazone in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The objective of the study was to investigate whether there is a drug-drug interaction between BI 10773 and pioglitazone when co-administered as multiple oral doses. Therefore, the relative bioavailabilities of BI 10773 and pioglitazone were determined when both drugs were given in combination compared with BI 10773 and pioglitazone given alone.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males according to the following criteria:

    • Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (electrocardiogram), clinical laboratory tests
  • Age 18 to 50 years (incl.)
  • 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including BP, PR and ) deviating from normal and of clinical relevance
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/ (including allergy to drug or its )
  • Intake of drugs with a long half-life (more than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Participation in another trial with an drug within two months prior to administration or during the trial
  • Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (more than 30 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • (Alanine transaminase) outside the normal range or any other laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • Galactose or lactose intolerance, galactose or glucose malabsorption
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sequence ABC

    1. Treatment A: 50 mg BI 10773 once daily from day 1 to 5 2. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7 3. Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out

    Drug: BI 10773 · Drug: Pioglitazone

  • Experimental
    Sequence CAB

    1. Treatment C: 45 mg pioglitazone once daily from day 1 to 7 2. Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out 3. Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7

    Drug: BI 10773 · Drug: Pioglitazone

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 10 days

  2. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 10 days

Secondary outcomes

  1. Abnormal findings in physical examination

    Time frame: Baseline and up to 10 days after last study drug administration

  2. Changes from baseline in vital signs (Blood pressure, pulse rate)

    Time frame: Baseline and up to 10 days after last study drug administration

  3. Changes from baseline in 12-lead ECG (electrocardiogram)

    Time frame: Baseline and up to 10 days after last study drug administration

  4. Changes in clinical laboratory tests

    Time frame: Baseline and up to 10 days after last study drug administration

  5. Incidence of adverse events

    Time frame: up to 35 days

  6. Assessment of tolerability by investigator on a 4-point scale

    Time frame: Within 3-10 days after last study drug administration

  7. C24,N (concentration of analyte in plasma at 24 hours post-drug administration after administration of the Nth dose)

    Time frame: up to 10 days

  8. λz,ss (terminal half-life of the analyte in plasma)

    Time frame: up to 10 days

  9. t½,ss (terminal half-life of the analyte in plasma at steady state)

    Time frame: up to 10 days

  10. tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 10 days

  11. MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)

    Time frame: up to 10 days

  12. CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)

    Time frame: up to 10 days

  13. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)

    Time frame: up to 10 days

  14. Aet1-t2,ss (amount of analyte eliminated in urine at steady state over a uniform dosing interval τ)

    Time frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing

  15. fet1-t2,ss (fraction of analyte excreted unchanged in urine at steady state over a uniform dosing interval τ)

    Time frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing

  16. CLR,ss (renal clearance of the analyte at steady state)

    Time frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing

  17. UGE0-24 (Urinary glucose excretion of the analyte in urine over the time interval from time zero to 24 h)

    Time frame: 1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009 and a primary completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2014
First posted
Oct 28, 2014
Start
Jun 2009
Primary completionActual
Jul 2009
Last update
Oct 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02276365
Responsible party
Sponsor
First posted
Oct 28, 2014
Start date
Jun 2009
Primary completion
Jul 2009
Last update
Oct 28, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion